NAMCP Medical Directors Institute Home
AAMCN
Managed Care Nurses Association Home
Continuing Education Home

 

Business/Practice Management
CME Online

The newest CME presentations are at the top of this page.
Those nearing expiration are nearer the bottom of the page.

Business/Practice Management Preventive Health & Lifestyle Medicine Chronic Illness
Behavioral Health Oncology Genomics, Biotech & Emerging Medical Technologies

 

Overcoming Challenges in the Emerging Biosimilar Landscape
Biologic agents have revolutionized the treatment of many diseases, including cancer, diabetes, hepatitis, inflammatory bowel disease, and rheumatoid arthritis. A biosimilar is a biologic drug that is developed to be highly similar, but not identical, to an existing biologic. Although there are minor differences in clinically inactive components, they cannot have a clinically meaningful difference between the biological product and the reference product in terms of the safety, efficacy and potency. Along with their sensitivity and size, biologic medicines are almost always injected into a patient’s body and the way a patient responses to that treatment can depend on how a biologic is made. Since the complexity of biologic medicines is well documented along with their complex production, biosimilars must be determined on the basis of analytical, non-clinical and clinical data to be similar to an original biologic in structural characteristics, safety and efficacy. Small differences with the active ingredient are expected and permitted so long as any such differences are demonstrated not to be clinically meaningful. Now, with patents continuing to expire on these first biologics, biosimilar products are becoming available. These agents are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers.
Physician, Nursing and CMCN credits valid to January 31, 2018
 
Trends and Opportunities in Improving Population Health with Telemedicine
Telemedicine has been practiced for years, but with ACA, improved internet access and other healthcare technologies, it is making a surge and not just in rural communities. The speaker will review the current landscape and provide trends and potential resources for improving patient outcomes. Additionally, the role of telemedicine and healthcare technology can and will have a tremendous impact but of course what methods are there and what is recommended. A truly must see session!
Physician, Nursing and CMCN credits valid to January 31, 2018
 
The Future of Healthcare - Optimization of Value Based Clinical and Business Models
This presentation will highlight factors spearheading future healthcare strategies and how to optimize value based clinical and business models. It is an in-depth analysis and review of the evolving marketplace. Our discussion will include:
   (1) The factors effecting individual market transition;
   (2) Insurance products driving clinical revenue stream changes;
   (3) Are Super CINs, CINs, ACOs, and Specialty CINs working or not;
   (4) Specialty CINs – changing structures and bundled payments;
   (5) Physician Management Re- Invented; and
   (6) the rules for Physicians, Hospitals and Boards that are in play.

Physician, Nursing and CMCN credits valid to September 30, 2017
 
The Role of Hospice in Reducing Hospital Readmissions
Many patients who are readmitted to hospitals suffer from advanced disease. These patients face high risk for complications, prolonged stays, and frequent transitions. Hospice providers work closely with patients and families to identify care preferences, manage symptoms, and address clinical, emotional and spiritual needs through a team-oriented, interdisciplinary approach. This type of care allows patients to pick up the phone in a time of crisis and receive emergency medications at home, or a facility, without returning to the hospital. Integrating palliative care early, and making timely and appropriate hospice referrals can not only improve patient experiences, but address some of the most important issues faced by hospitals today: quality improvement, overcrowding in the Emergency Department and ICU, increasing coordination, preventing complications, reducing costs – and ultimately, return trips to the hospital in a patient’s final stages of life when comfort matters most.
Physician, Nursing and CMCN credits valid to September 30, 2017
 
Exploring the Recent Advances of Biosimilars
Since the complexity of biologic medicines is well documented along with their complex production, biosimilars must be determined on the basis of analytical, non-clinical and clinical data to be similar to an original biologic in structural characteristics, safety and efficacy. Small differences with the active ingredient are expected and permitted so long as any such differences are demonstrated not to be clinically meaningful. The patents of a growing number of biologic medicines have already expired and will continue to expire, which has led to an increased interest in the development of biosimilars. With patents expiring over the next several years, we will continue to see a new generation of complex biosimilars being developed as numerous leading biologic medicines, worth an estimated $81 billion in global annual sales.
Physician, Nursing and CMCN credits valid to July 31, 2017